Promethazine protects against 3-nitropropionic acid-induced neurotoxicity

Neurochemistry International

Volumn 56, Issue 2, 2010, Pages 208-212

  Cleren, Carine ^a   Calingasan, Noel Y ^a   Starkov, Anatoly ^a   Jacquard, Carine ^b   Chen, Junya ^a   Brouillet, Emmanuel ^b   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

Apoptosis; Calbindin; Huntington; Mitochondria; Neuroprotection; Neurotoxicity; Succinate dehydrogenase

Indexed keywords

3 NITROPROPIONIC ACID; CALBINDIN; NEURON SPECIFIC NUCLEAR PROTEIN; PROMETHAZINE; SUCCINATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; GABAERGIC SYSTEM; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; MALE; MICE; NEUROPROTECTIVE AGENTS; NITRO COMPOUNDS; PROMETHAZINE; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; SUCCINATE DEHYDROGENASE;

MUS; RATTUS;

EID: 77149169404     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.10.006     Document Type: Article

References (33)

1. Alston T.A., Mela L., Bright H.J. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad. Sci. 1977, 74:3767-3771.
2. Arrigon O., Singer T. Limitations of the phenazine methosulfate assay for succinic and related dehydrogenases. Nature 1962, 193:1256-1258.
3. 2+-induced permeability transition in energized liver mitochondria discriminates between inhibitor mechanisms. J. Biol. Chem. 2008, 283:665-676.
4. Beal M.F., Ferrante R.J., Henshaw R., Matthews R.T., Chan P.H., Kowall N.W., Epstein C.J., Schulz J.B. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 1995, 65:919-922.
5. Beal M.F., Brouillet E., Jenkins B.G., Ferrante R.J., Kowall N.W., Miller J.M., Storey E., Srivastava R., Rosen B.R., Hyman B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 1993, 13:4181-4192.
6. Bizat N., Galas M.C., Jacquard C., Boyer F., Hermel J.M., Schiffmann S.N., Hantraye P., Blum D., Brouillet E. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology 2005, 49:695-702.
7. Bizat N., Hermel J.M., Boyer F., Jacquard C., Creminon C., Ouary S., Escartin C., Hantraye P., Kajewski S., Brouillet E. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci. 2003, 23:5020-5030.
8. Bizat N., Hermel J.M., Humbert S., Jacquard C., Creminon C., Escartin C., Saudou F., Krajewski S., Hantraye P., Brouillet E. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J. Biol. Chem. 2003, 278:43245-43253.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
10. Bogdanov M.B., Ferrante R.J., Mueller G., Ramos L.E., Martinou J.C., Beal M.F. Oxidative stress is attenuated in mice overexpressing BCL-2. Neurosci. Lett. 1999, 262:33-36.
11. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95:1521-1540.
12. Brouillet E., Conde F., Beal M.F., Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59:427-468.
13. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
14. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
15. Cleren C., Starkov A.A., Calingasan N.Y., Lorenzo B.J., Chen J., Beal M.F. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiol. Dis. 2005, 20:701-708.
16. Harper P. Huntington's Disease 1991, Saunders, London.
17. Jacquard C., Trioulier Y., Cosker F., Escartin C., Bizat N., Hantraye P., Cancela J.M., Bonvento G., Brouillet E. Brain mitochondrial defects amplify intracellular. (Ca2+) rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J. 2006, 20:1021-1023.
18. Klivenyi P., Starkov A.A., Calingasan N.Y., Gardian G., Browne S.E., Yang L., Bubber P., Gibson G.E., Patel M.S., Beal M.F. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. J. Neurochem. 2004, 88:1352-1360.
19. Muller T. Electron microscopic demonstration of intracellular promethazine accumulation sites by a precipitation technique: application to the cerebellar cortex of the mouse. J. Histochem. Cytochem. 1996, 44:531-535.
20. Narayanan M.V., Zhang W., Stavrovskaya I.G., Kristal B.S., Friedlander R.M. Promethazine: a novel application as a neuroprotectant that reduces ischemia-mediated injury by inhibiting mitochondrial dysfunction. Clin. Neurosurg. 2004, 51:102-107.
21. Nasr P., Gursahani H.I., Pang Z., Bondada V., Lee J., Hadley R.W., Geddes J.W. Influence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropionic acid. Neurochem. Int. 2003, 43:89-99.
22. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P., Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implication for neuroprotection studies. Neuroscience 2000, 97:521-530.
23. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5:731-736.
24. Schulz J.B., Henshaw D.R., Siwek D., Jenkins B.G., Ferrante R.J., Cipolloni P.B., Kowall N.W., Rosen B.R., Beal M.F. Involvement of free radicals in excitotoxicity in vivo. J. Neurochem. 1995, 64:2239-2247.
25. Shih A.Y., Imbeault S., Barakauskas V., Erb H., Jiang L., Li P., Murphy T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem. 2005, 280:22925-22936.
26. Stavrovskaya I.G., Narayanan M.V., Zhang W., Krasnikov B.F., Heemskerk J., Young S.S., Blass J.P., Brown A.M., Beal M.F., Friedlander R.M., Kristal B.S. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J. Exp. Med. 2004, 200:211-222.
27. Sugino T., Nozaki K., Tokime T., Hashimoto N., Kikuchi H. 3-Nitropropionic acid induces poly(ADP-ribosyl)ation and apoptosis related gene expression in the striatum in vivo. Neurosci. Lett. 1997, 237:121-124.
28. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
29. Wang H., Guan Y., Wang X., Smith K., Cormier K., Zhu S., Stavrovskaya I.G., Huo C., Ferrante R.J., Kristal B.S., Friedlander R.M. Nortriptyline delays disease onset in models of chronic neurodegeneration. Eur. J. Neurosci. 2007, 26:633-641.
30. Yang L., Calingasan N.Y., Chen J., Ley J.J., Becker D.A., Beal M.F. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. 2005, 191:86-93.
31. Yang L., Calingasan N.Y., Thomas B., Chaturvedi R.K., Kiaei M., Wille E.J., Liby K.T., Williams C., Royce D., Risingsong R., Musiek E.S., Morrow J.D., Sporn M., Beal M.F. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf-2 mediated transcription. PLoS One 2009, 4:e5757.
32. Yang L., Calingasan N.Y., Wille E.J., Cormeir K., Smith K., Ferrante R.J., Beal M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 209:1427-1439.
33. Yang L., Sugama S., Mischak R.P., Kiaei M., Bizat N., Brouillet E., Joh T.H., Beal M.F. A novel systematically active caspase inhibitor attenuates the toxicities of MPTP, malonate and 3NP in vivo. Neurobiol. Dis. 2004, 17:250-259.